Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.46
-2.2750-1.07%
Post-market: 209.500.0400+0.02%19:50 EDT
Volume:2.12M
Turnover:444.42M
Market Cap:44.89B
PE:-23.48
High:212.74
Open:212.06
Low:206.75
Close:211.74
52wk High:220.34
52wk Low:35.62
Shares:214.34M
Float Shares:184.00M
Volume Ratio:1.37
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.23
PE(LYR):-35.20

Loading ...

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $478,465.61

Reuters
·
May 29

Analysts Conflicted on These Healthcare Names: CVS Health (CVS), Revolution Medicines (RVMD) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 27

What Revolution Medicines (RVMD)'s Phase 3 Daraxonrasib Survival Data Means For Shareholders

Simply Wall St.
·
May 24

Revolution Medicines Initiated at Market Perform by Bernstein

Dow Jones
·
May 22

Bernstein Initiates Revolution Medicines at Market Perform

MT Newswires Live
·
May 22

Bernstein starts Revolution Medicines at Market Perform, says upside baked in

TIPRANKS
·
May 22

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

GlobeNewswire
·
May 22

Cantargia Q1 FY26 operating loss narrows to SEK 36.9 million; net sales rise to SEK 0.5 million

Reuters
·
May 19

Revolution Medicines Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 19

Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential

TIPRANKS
·
May 15

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

Reuters
·
May 14

LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
May 10

Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom

Reuters
·
May 08

Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry

TIPRANKS
·
May 08

Revolution Medicines price target raised to $185 from $170 at BofA

TIPRANKS
·
May 08

Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
May 07

Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality

TIPRANKS
·
May 07

RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 07

Revolution Medicines Inc : JP Morgan Raises Target Price to $200 From $175

THOMSON REUTERS
·
May 07

Wedbush Raises Price Target on Revolution Medicines to $165 From $147, Keeps Outperform Rating

MT Newswires Live
·
May 07